Profile data is unavailable for this security.
About the company
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
- Revenue in USD (TTM)13.17m
- Net income in USD-158.43m
- Incorporated2016
- Employees174.00
- LocationGeneration Bio Co301 BINNEY STREETCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 529-5908
- Fax+1 (302) 655-5049
- Websitehttps://generationbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunic Inc | 0.00 | -95.31m | 161.24m | 77.00 | -- | 2.54 | -- | -- | -1.51 | -1.51 | 0.00 | 0.7058 | 0.00 | -- | -- | 0.00 | -108.78 | -72.09 | -141.92 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
Ventyx Biosciences Inc | 0.00 | -171.30m | 161.83m | 73.00 | -- | 0.5763 | -- | -- | -2.79 | -2.79 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.07 | -- | -55.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
P3 Health Partners Inc | 1.40bn | -69.48m | 164.55m | 400.00 | -- | 0.446 | -- | 0.1173 | -0.5821 | -0.5821 | 11.56 | 1.03 | 1.56 | -- | 10.97 | 3,507,143.00 | -20.51 | -- | -110.70 | -- | 0.6223 | 0.1781 | -13.17 | -56.93 | -- | -9.67 | 0.2686 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
Lineage Cell Therapeutics Inc | 6.19m | -24.19m | 166.18m | 75.00 | -- | 2.43 | -- | 26.86 | -0.1342 | -0.1342 | 0.0343 | 0.3617 | 0.0577 | -- | 18.25 | 82,480.00 | -22.57 | -19.53 | -26.03 | -22.59 | 90.83 | 89.13 | -391.25 | -370.88 | -- | -- | 0.0017 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Capricor Therapeutics Inc | 27.15m | -27.95m | 166.60m | 101.00 | -- | 14.24 | -- | 6.14 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
Galectin Therapeutics Inc | 0.00 | -48.03m | 168.77m | 14.00 | -- | -- | -- | -- | -0.7831 | -0.7831 | 0.00 | -1.32 | 0.00 | -- | -- | 0.00 | -185.54 | -92.08 | -382.33 | -121.97 | -- | -- | -- | -- | -- | -8.59 | 8.29 | -- | -- | -- | -15.26 | -- | -- | -- |
Generation Bio Co | 13.17m | -158.43m | 172.86m | 174.00 | -- | 1.50 | -- | 13.12 | -2.39 | -2.39 | 0.1989 | 1.73 | 0.0393 | -- | 77.49 | 75,712.64 | -47.28 | -36.96 | -51.64 | -39.21 | -- | -- | -1,202.56 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
Shattuck Labs Inc | 4.12m | -85.28m | 174.20m | 75.00 | -- | 1.57 | -- | 42.24 | -1.85 | -1.85 | 0.0883 | 2.32 | 0.029 | -- | -- | 54,986.67 | -60.08 | -29.14 | -66.66 | -32.42 | -- | -- | -2,067.99 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
Sangamo Therapeutics Inc | 12.28m | -249.68m | 174.30m | 405.00 | -- | 7.36 | -- | 14.20 | -1.38 | -1.38 | 0.0664 | 0.1138 | 0.0587 | -- | 7.45 | 30,313.58 | -119.44 | -26.09 | -153.51 | -31.04 | -- | -- | -2,033.68 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
Inovio Pharmaceuticals Inc | 591.86k | -121.64m | 175.78m | 122.00 | -- | 1.82 | -- | 296.99 | -5.11 | -5.11 | 0.0248 | 3.73 | 0.0032 | -- | 0.6652 | 4,851.31 | -66.32 | -59.52 | -84.33 | -71.29 | -- | -- | -20,552.24 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
DiaMedica Therapeutics Inc | 0.00 | -19.90m | 176.55m | 18.00 | -- | 3.30 | -- | -- | -0.5238 | -0.5238 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -33.49 | -45.38 | -34.98 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
Atossa Therapeutics Inc | 0.00 | -25.91m | 178.58m | 10.00 | -- | 2.23 | -- | -- | -0.2064 | -0.2064 | 0.00 | 0.6374 | 0.00 | -- | -- | 0.00 | -26.68 | -29.97 | -28.00 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
Holder | Shares | % Held |
---|---|---|
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 9.41m | 14.11% |
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 5.30m | 7.95% |
Bellevue Asset Management AGas of 30 Jun 2024 | 3.92m | 5.87% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 3.01m | 4.51% |
Invus Public Equities Advisors LLCas of 30 Jun 2024 | 2.83m | 4.24% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 2.54m | 3.81% |
Bank of America, NA (Private Banking)as of 30 Jun 2024 | 2.13m | 3.19% |
EcoR1 Capital, LLCas of 30 Jun 2024 | 2.05m | 3.07% |
Baker Bros. Advisors LPas of 30 Jun 2024 | 1.21m | 1.81% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.14m | 1.70% |